OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:330009
Who is this for?
Show terms as
8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

This entry refers to poliomyelitis (polio) that occurs specifically in people who have weakened immune systems (immunodeficiencies) and who are considered at higher risk for developing the disease. Polio is caused by the poliovirus, which attacks the nervous system and can lead to muscle weakness or paralysis. In people with healthy immune systems, vaccination has made polio extremely rare. However, individuals with certain immune deficiencies — particularly those affecting antibody production — may not be able to mount a proper immune response to the oral polio vaccine (OPV), which contains a live but weakened virus. In these vulnerable patients, the vaccine virus can persist in the body, mutate, and eventually cause vaccine-derived poliomyelitis. This condition can affect the spinal cord and brainstem, leading to limb paralysis, breathing difficulties, and in severe cases, life-threatening complications. It is important to note that this Orphanet entry is marked as OBSOLETE, meaning it may have been reclassified or merged into other disease categories. The condition highlights the intersection of primary immunodeficiency disorders and infectious disease risk. Symptoms can include sudden onset of limb weakness, muscle pain, difficulty swallowing, and respiratory failure. Treatment is largely supportive, as there is no antiviral cure for poliovirus infection. Management focuses on physical rehabilitation, respiratory support, and addressing the underlying immune deficiency through immunoglobulin replacement therapy. Prevention through use of inactivated polio vaccine (IPV) instead of oral polio vaccine in immunodeficient individuals is a critical public health strategy.

Key symptoms:

Sudden muscle weakness in one or more limbsParalysis, often affecting the legsMuscle pain and stiffnessFeverFatigue and general feeling of being unwellDifficulty swallowingBreathing difficultiesNeck stiffnessHeadacheLoss of reflexes in affected limbsMuscle wasting over timeFrequent infections due to underlying immune deficiencyChronic diarrhea (related to persistent virus in the gut)

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
Oct 2020

Bronchitol®: FDA approved

as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.

FDAcompleted
Feb 2013

Ravicti: FDA approved

Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk community →

No specialists are currently listed for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

Ravicti

Horizon Therapeutics USA, Inc.

Ravicti Patient Support (Horizon Patient Services)

Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at riskForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.

Start the conversation →

Latest news about OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk

No recent news articles for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What type of immunodeficiency does my child or I have, and how does it increase the risk of polio?,Should all family members receive the inactivated polio vaccine instead of the oral vaccine?,How often will immunoglobulin replacement therapy be needed, and what are the side effects?,What signs of worsening should I watch for that would require emergency care?,What physical therapy or rehabilitation options are available to maximize recovery?,Is genetic testing recommended for other family members to check for the same immune deficiency?,Are there any clinical trials or new treatments being studied for this condition?

Common questions about OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk

What is OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk?

This entry refers to poliomyelitis (polio) that occurs specifically in people who have weakened immune systems (immunodeficiencies) and who are considered at higher risk for developing the disease. Polio is caused by the poliovirus, which attacks the nervous system and can lead to muscle weakness or paralysis. In people with healthy immune systems, vaccination has made polio extremely rare. However, individuals with certain immune deficiencies — particularly those affecting antibody production — may not be able to mount a proper immune response to the oral polio vaccine (OPV), which contains a

What treatment and support options exist for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk?

1 patient support program are currently tracked on UniteRare for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk. See the treatments and support programs sections for copay assistance, eligibility, and contact details.